Overview

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus